Apo-Form Selective Inhibition of IDO for Tumor Immunotherapy.
Liu W, Zou Y, Li K, Zhong H, Yu L, Ge S, Lai Y, Dong X, Xu Q, Guo W.
Liu W, et al. Among authors: xu q.
J Immunol. 2022 Jul 1;209(1):180-191. doi: 10.4049/jimmunol.2100938. Epub 2022 Jun 20.
J Immunol. 2022.
PMID: 35725271